CTNM Stock Overview

Profile

Full Name:

Contineum Therapeutics, Inc.

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

Indexes:

Not included

Website:

http://www.contineum-tx.com

Description:

Contineum Therapeutics focuses on developing innovative therapies for chronic diseases. The company leverages advanced biotechnology to create targeted treatments, aiming to improve patient outcomes and enhance quality of life. Their research emphasizes precision medicine and cutting-edge drug delivery systems.

Key Details

Price

$9.11

Market Cap

$234.84 M(Small cap)

Last Dividend

-

TTM Dividend Yield

-

Annual Revenue

$50.00 M

Annual EPS

$1.12(+177.00% YoY)

PE Ratio

-

Annual ROE

-33.44%

Annual Debt To Equity

0.00

Beta

1.59

Events Calendar

Earnings

Next earnings date:

Feb 28, 2025

Recent quarterly earnings:

Nov 6, 2024

Recent annual earnings:

N/A
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

N/A

Analyst ratings

Recent major analysts updates

Jan 9, 25 RBC Capital
Outperform
Nov 7, 24 RBC Capital
Outperform
Oct 22, 24 Baird
Outperform
Aug 14, 24 RBC Capital
Outperform
Apr 30, 24 Stifel
Buy
Apr 30, 24 RBC Capital
Outperform
Apr 30, 24 Morgan Stanley
Overweight

Screeners with CTNM included

US stocks
Stocks with high beta
Stocks below SMA 200
Most recommended stocks
Stocks below analysts price target
Healthcare sector
All stocks
Companies with buyback
Biotechnology industry
Stocks with low RSI

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price

Current Price

$9.11
CTNM price is $9.11

Price All-time High

$22.50
CTNM price is currently -59.51% below its historical high of $22.50

Price Analysts Target

$30.00
CTNM price is currently -69.63% lower than the consensus analysts' forecast

Price Today Change

-3.8%
CTNM price is down -3.8% today

Price YTD Change

-37.82%
CTNM price is down -37.82% since January 1st

Price 3-Year Change

-
CTNM price 3-year change is unknown

Market cap

Market Cap

$234.84 M
CTNM market capitalization is $234.84 million

Market Cap 3-Year Change

-
CTNM market capitalization 3-year change is unknown

Market Cap All-time High

$565.44 M
CTNM market capitalization is currently -58.47% below its historical high of $565.44 million

Market Cap Sector Rank

56.16%
CTNM market capitalization is higher than 56.16% of companies in Healthcare sector

Technical

Beta

1.59
CTNM beta is 1.59

200-day SMA

$16.52
CTNM price is currently -44.86% below its 200-day simple moving average

14-day RSI

19.46
CTNM 14-day relative strength index is 19.46

30-day Relative Volume

0.66
CTNM 30-day relative volume is 0.66

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Annual Revenue

$50.00 M
CTNM annual revenue is $50.00 million

Annual Revenue Analysts Estimate

-
CTNM annual revenue consensus analysts' forecast is unknown

Annual Revenue 1-Year Change

-
CTNM annual revenue 1-year change is unknown

Annual Revenue Sector Rank

47.29%
CTNM annual revenue is higher than 47.29% of companies in Healthcare sector

Profit

Annual Gross Profit

-
CTNM annual gross profit value is unknown

Annual Gross Margin

-
CTNM annual gross profit margin value is unknown

Annual Operating Profit

$16.08 M
CTNM annual operating income is $16.08 million

Annual Operating Margin

32.15%
CTNM annual operating profit margin is 32.15%

Annual Net Income

$22.72 M
CTNM annual net profit is $22.72 million

Annual Net Margin

45.44%
CTNM annual net profit margin is 45.44%

EPS

Annual EPS

$1.12
CTNM annual earnings per share is $1.12

Annual EPS Analysts Estimate

-$1.90
CTNM annual earnings per share is currently -158.87% lower than the consensus analysts' forecast

Annual EPS 1-Year Change

+177%
CTNM annual earnings per share is up +177% year-on-year

Annual EPS Sector Rank

89.98%
CTNM annual earnings per share is higher than 89.98% of companies in Healthcare sector

ROA & ROE

Annual ROA

17.43%
CTNM annual return on assets is 17.43%

Annual ROE

-33.44%
CTNM annual return on equity is -33.44%

EBIT & EBITDA

Annual EBIT

$23.38 M
CTNM annual earnings before interest & taxes is $23.38 million

Annual EBITDA

$23.57 M
CTNM annual EBITDA is $23.57 million

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PE Ratio

-
CTNM price to earnings ratio value is unknown

PE Ratio Sector Rank

-
CTNM price to earnings ratio is unknown

PB Ratio

PB Ratio

1.12
CTNM price to book ratio is 1.12

PB Ratio Sector Rank

43.06%
CTNM price to book ratio is higher than 43.06% of companies in Healthcare sector

PS Ratio

PS Ratio

-
CTNM price to sales ratio value is unknown

PS Ratio Sector Rank

-
CTNM price to sales ratio is unknown

Enterprise value

Enterprise Value

$194.56 M
CTNM enterprise value is $194.56 million

Enterprise Value Sector Rank

55.47%
CTNM enterprise value is higher than 55.47% of companies in Healthcare sector

EV/EBITDA

EV/EBITDA

-5.50
CTNM EV/EBITDA is -5.50

EV/EBITDA Sector Rank

22.12%
CTNM EV/EBITDA is higher than 22.12% of companies in Healthcare sector

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Annual Current Ratio

23.29
CTNM annual current ratio is 23.29

Annual Quick Ratio

-
CTNM annual quick ratio value is unknown

Leverage

Annual Debt To Equity

0.00
CTNM annual debt to equity ratio is 0.00

Annual Interest Coverage Ratio

112.39
CTNM annual interest coverage ratio is 112.39

Risk & Stability

Piotroski F-Score

-
CTNM piotroski f-score value is unknown

Altman Z-Score

2.00
CTNM altman z-score is 2.00

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Annual Total Assets

$130.39 M
CTNM annual total assets is $130.39 million

Annual Non Current Assets

$2.68 M
CTNM annual long term assets is $2.68 million

Annual Current Assets

$127.71 M
CTNM annual total current assets is $127.71 million

Annual Cash & Cash Equivalents

$15.53 M
CTNM annual cash & cash equivalents is $15.53 million

Equity

Annual Book Value

-$67.94 M
CTNM annual book value is -$67.94 million

Annual Working Capital

$122.22 M
CTNM annual working capital is $122.22 million

Liabilities

Annual Total Liabilities

$198.32 M
CTNM annual total liabilities is $198.32 million

Annual Total Long Term Liabilities

$192.84 M
CTNM annual total long term liabilities is $192.84 million

Annual Current Liabilities

$5.48 M
CTNM annual total current liabilities is $5.48 million

Annual Accounts Payable

$635.00 K
CTNM annual accounts payable is $635.00 thousand

Debt

Annual Total Debt

$572.00 K
CTNM annual total debt is $572.00 thousand

Annual Total Debt 1-Year Change

-90.22%
CTNM annual total debt is down -90.22% year-on-year

Annual Long Term Debt

$108.00 K
CTNM annual long term debt is $108.00 thousand

Annual Short Term Debt

$464.00 K
CTNM annual short term debt is $464.00 thousand

Expenses

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Annual Total Expenses

$33.92 M
CTNM annual total expenses is $33.92 million

Annual Operating Expenses

$33.92 M
CTNM annual total operating expenses is $33.92 million

Annual Cost Of Goods Sold

-
CTNM annual cost of goods sold value is unknown

Annual SGA

$6.32 M
CTNM annual SGA is $6.32 million

Annual D&A

$195.00 K
CTNM annual depreciation & amortization is $195.00 thousand

Annual Interest Expense

$208.00 K
CTNM annual interest expense is $208.00 thousand

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Annual CFO

$19.35 M
CTNM annual cash flow from operations is $19.35 million

Annual CFO 1-Year Change

+196.16%
CTNM annual cash flow from operations is up +196.16% year-on-year

Annual CFI

-$65.57 M
CTNM annual cash flow from investing activities is -$65.57 million

Annual CFI 1-Year Change

-394.04%
CTNM annual cash flow from investing activities is down -394.04% year-on-year

Annual CFF

$56.18 M
CTNM annual cash flow from financing activities is $56.18 million

Annual CFF 1-Year Change

+4633.98%
CTNM annual cash flow from financing activities is up +4633.98% year-on-year

Free CashFlow

Annual FCF

$18.93 M
CTNM annual free cash flow is $18.93 million

Annual FCF 1-Year Change

+193.56%
CTNM annual free cash flow is up +193.56% year-on-year

CAPEX

Annual CAPEX

$414.00 K
CTNM annual capital expenditures is $414.00 thousand

Annual CAPEX 1-Year Change

-
CTNM annual capital expenditures 1-year change is unknown

Institutional Ownership

Similar stocks

RCEL logo
AVITA Medical (RCEL)
TVGN logo
Tevogen Bio Holdings (TVGN)
PRQR logo
ProQR Therapeutics NV (PRQR)
MNPR logo
Monopar Therapeutics (MNPR)
HITI logo
High Tide (HITI)
AMRN logo
Amarin (AMRN)
AMLX logo
Amylyx Pharmaceuticals (AMLX)
SOPH logo
SOPHiA GENETICS SA (SOPH)
CRDF logo
Cardiff Oncology (CRDF)
Contineum Therapeutics Completes Enrollment in Phase 2 PIPE-307 VISTA Trial for the Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS)
Contineum Therapeutics Completes Enrollment in Phase 2 PIPE-307 VISTA Trial for the Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS)
Contineum Therapeutics Completes Enrollment in Phase 2 PIPE-307 VISTA Trial for the Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS)
CTNM
businesswire.comJanuary 8, 2025

SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced that it has completed the targeted enrollment of 168 patients in its Phase 2 PIPE-307 VISTA trial. PIPE-307 is a potentially first-in-class M1 receptor antagonist in development for patients with relapsing-remitting m.

Contineum Therapeutics to Present at the 45th Annual Goldman Sachs Healthcare Conference
Contineum Therapeutics to Present at the 45th Annual Goldman Sachs Healthcare Conference
Contineum Therapeutics to Present at the 45th Annual Goldman Sachs Healthcare Conference
CTNM
businesswire.comJune 4, 2024

SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (Nasdaq: CTNM), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced that Company management will participate in the 45th Annual Goldman Sachs Healthcare Conference, taking place June 10-13, 2024.

U.S. IPO Weekly Recap: April IPO Market Gets A Boost From Large Launches And New Filings
U.S. IPO Weekly Recap: April IPO Market Gets A Boost From Large Launches And New Filings
U.S. IPO Weekly Recap: April IPO Market Gets A Boost From Large Launches And New Filings
CTNM
Seeking AlphaApril 6, 2024

U.S. IPO Weekly Recap: April IPO Market Gets A Boost From Large Launches And New Filings

CTNM Stock: 7 Things to Know as Contineum Therapeutics Starts Trading Today
CTNM Stock: 7 Things to Know as Contineum Therapeutics Starts Trading Today
CTNM Stock: 7 Things to Know as Contineum Therapeutics Starts Trading Today
CTNM
InvestorPlaceApril 5, 2024

Contineum Therapeutics (NASDAQ:CTNM) stock is a hot topic among traders on Friday as they prepare for the clinical-stage biopharmaceutical company's shares to go public today. Let's go over everything traders need to know about Contineum Therapeutics ahead of its initial public offering ( IPO ) later today!

FAQ

  • What is the ticker symbol for Contineum Therapeutics Class A?
  • Does Contineum Therapeutics Class A pay dividends?
  • What sector is Contineum Therapeutics Class A in?
  • What industry is Contineum Therapeutics Class A in?
  • What country is Contineum Therapeutics Class A based in?
  • Is Contineum Therapeutics Class A in the S&P 500?
  • Is Contineum Therapeutics Class A in the NASDAQ 100?
  • Is Contineum Therapeutics Class A in the Dow Jones?
  • When was Contineum Therapeutics Class A's last earnings report?
  • When does Contineum Therapeutics Class A report earnings?
  • Should I buy Contineum Therapeutics Class A stock now?

What is the ticker symbol for Contineum Therapeutics Class A?

The ticker symbol for Contineum Therapeutics Class A is NASDAQ:CTNM

Does Contineum Therapeutics Class A pay dividends?

No, Contineum Therapeutics Class A does not pay dividends

What sector is Contineum Therapeutics Class A in?

Contineum Therapeutics Class A is in the Healthcare sector

What industry is Contineum Therapeutics Class A in?

Contineum Therapeutics Class A is in the Biotechnology industry

What country is Contineum Therapeutics Class A based in?

Contineum Therapeutics Class A is headquartered in United States

Is Contineum Therapeutics Class A in the S&P 500?

No, Contineum Therapeutics Class A is not included in the S&P 500 index

Is Contineum Therapeutics Class A in the NASDAQ 100?

No, Contineum Therapeutics Class A is not included in the NASDAQ 100 index

Is Contineum Therapeutics Class A in the Dow Jones?

No, Contineum Therapeutics Class A is not included in the Dow Jones index

When was Contineum Therapeutics Class A's last earnings report?

Contineum Therapeutics Class A's most recent earnings report was on Nov 6, 2024

When does Contineum Therapeutics Class A report earnings?

The next expected earnings date for Contineum Therapeutics Class A is Feb 28, 2025

Should I buy Contineum Therapeutics Class A stock now?

As of today, analysts generally recommend a 'Strong buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions